HEALTH OF WOMAN. 2016.6(112):66–72; doi 10.15574/HW.2016.112.66 
 

Results of using the domestic synbiotic Bifiten for treatment of bacterial vaginosis of pregnant women 
 

Tsmur O., Levchuk O., Liashyna K., Boyko N.

Uzhgorod city maternity hospital

Department of obstetrics and ginekologiya of SHEI «Uzhgorod national University»

Research and training centre of molecular Microbiology and immunology of the mucous membranes

SHEI «Uzhgorod national University» Clinical diagnostic laboratory PP «ASTRA-DIA», Uzhgorod

The article shows the research results of vaginal microbiome correction of pregnant women with bacterial vaginosis before and after oral using of synbiotic Bifiten. This biopreparation differs from others recommended for vaginal microbiome correction by its combined anti-inflammatory and specific pro- and antimicrobial activity.

The aim of research is to define the clinical efficacy of oral administration of the non-medicinal biological (synbiotic) preparation Bifiten to pregnant women with bacterial vaginosis.

Materials and Methods. Clinical and statistical analysis of pregnant women's individual cards, childbirth stories had been held. Vaginal microbiome had been studied by using classic microbiological methods and qRT-PCR. Immune parameters of vagina secrets had been detected by immunosorbent assay (ELISA).

Results. A positive dynamics of subjective and objective state of pregnant women had been observed. It was shown that following to the oral administration of Bifiten mucous membranes of vagina were settled by both commensal and transit microbiota, which in turn leads to reduction the perinatal complications for the mother and newborn. The effectiveness of the application of Bifiten against agents of gardnerellez and candidiasis is clinically proved.

Conclusion. Feasibility of using synbiotic Bifiten to treat pregnant women with bacterial vaginosis had been clinically proved. Good tolerability, complementarity or alternative taking with antibiotic therapy, no side effects, convenient form of release make reasonable to recommend it for the gynecology for the effective treatment of pregnant women with bacterial vaginosis.

Key words: bacterial vaginoses, vagina microbiome, synbiotic, aerobic and anaerobic pathogens, commensals, cytokines

REFERENCES

1.Vector-Best. Instruction to ELISA test-systems https://vector-best.ru/

2. Voronin КВ, Nahla Ben Saada, Chuico VI et al. 2012. Pregnants with bacterial vaginosis: ethiological diagnosis, prognosticacion and schedule of active prophylaxis of inflectional and prenatal complication. Taurian biomedical journal 15(2):40–43.

3. Kira EF. 2008. Probiotics in In gynecological practice ROAG-3b: 6-11.

4. Femoflor. Instruction to test-system Femoflor 16: http://dna-technology.ru/files/images/instructions_rus/femoflor/119-8_s__b_24-06-14.pdf.

5. Allsworth JE, Peipert JF. 2007. Prevalence of bacterial vaginosis. Obstet Gynecol. 109(1):114-20.

6. De Backer E, Verhelst R, Verstraelen H et al. 2006. Antibiotic susceptibility of Atopobium vaginae. BMC Infectious Diseases 6:51.

7. Dondersa G, Vereeckenb A, Bosmans E et al. 2002. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. International Journal of Obstetrics and Gynaecology January 109:34–43

8. Falagas ME, Betsi GI, Athanasiou S. 2007. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 13(7):657-64. http://dx.doi.org/10.1111/j.1469-0691.2007.01688.x; PMid:17633390

9. Jeppsson B, Mangell P, Adawi Diya, Molin G. 2004. Bacterial translocation: impact of probiotics Scandinavian Journal of Nutrition 48(1):37-41.

10. Ma B, Forney LJ, Jacques R. 2012. The vaginal microbiome: rethinking health and diseases. Annu Rev Microbiol. 66:371-389. http://dx.doi.org/10.1146/annurev-micro-092611-150157; PMid:22746335 PMCid:PMC3780402

11. MacPhee RA, Hummelen R, Bisanz JE et al. 2010. Probiotic strategy for the treatment and prevention of bacterial vaginosis. Expert Opin Pharmacother. 11(18):2985-95. http://dx.doi.org/10.1517/14656566.2010.512004; PMid:21080853

12. Reid G, Dols J, Miller W. 2009. Targeting the vaginal microbiota with probiotics as a means to counteract infections. Curr Opin Clin Nutr Met Care 12:583-7. http://dx.doi.org/10.1097/MCO.0b013e328331b611; PMid:19741517

13. Ribet D, Cossart P. 2015. How bacterial pathogens colonize their hosts and invade deeper tissues Microbes and Infection 17:173-183

14. Swidsinski A, Mendling W, Loening-Baucke V et al. 2005. Adherent biofilms in bacterial vaginosis. Obstet Gynecol; 106(5 Pt 1):1013-23.

15. Swidsinski A et al. 2008. An adherent Gardnerella vagina/is biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 198(1):97:1-6.

16. Turovskiy Y, Cheryian T, Algburi A et al. 2012. Susceptibility of Gardnerella vaginalis Biofilms to Natural Antimicrobials Subtilosin, ε-Poly-L-Lysine, and Lauramide Arginine Ethyl Este Infectious Diseases in Obstetrics and Gynecology:9. Article ID 284762

17. Verstraelen H. 2008. Cutting edge: the vaginal microflora and bacterial vaginosis. Verh K Acad Geneeskd Belg. 70(3):147-74.

18. Witkin SS, Linhares IN, Giraldo P, Ledger WJ. 2007. An altered immunity hypothesis for the development of symptomatic bacterial vaginosis. Clin Infect Dis. 44(4):554-7. http://dx.doi.org/10.1086/511045; PMid:17243059

19. Zareie M, Johnson-Henry K, Jury J et al. 2006. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress Gut. 55:1553–1560.